Search Results - "Damhuis, R A"

Comparison of 30-day, 90-day and in-hospital postoperative mortality for eight different cancer types by Damhuis, R. A. M., Wijnhoven, B. P. L., Plaisier, P. W., Kirkels, W. J., Kranse, R., van Lanschot, J. J.

“…Background: Various definitions are used to calculate postoperative mortality. As variation hampers comparability between reports, a study was performed to…”
Get full text

Optimising primary molecular profiling in non-small cell lung cancer by Schouten, R D, Schouten, I, Schuurbiers, M M F, van der Noort, V, Damhuis, R A M, van der Heijden, E H F M, Burgers, J A, Barlo, N P, van Lindert, A S R, Maas, K W, van den Brand, J J G, Smit, A A J, van Haarst, J M W, van der Maat, B, Schuuring, E, Blaauwgeers, H, Willems, S M, Monkhorst, K, van den Broek, D, van den Heuvel, M M

“…Molecular profiling of NSCLC is essential for optimising treatment decisions, but often incomplete. We assessed the efficacy of protocolised molecular…”
Get full text

Causes of postoperative mortality after surgery for ovarian cancer by Gerestein, C.G, Damhuis, R.A.M, de Vries, M, Reedijk, A, Burger, C.W, Kooi, G.S

“…Abstract Residual disease after cytoreductive surgery is an important prognostic factor in patients with advanced stage epithelial ovarian cancer (EOC)…”
Get full text

Understanding variations in survival for colorectal cancer in Europe: a EUROCARE high resolution study by Gatta, G, Capocaccia, R, Sant, M, Bell, C M J, Coebergh, J W W, Damhuis, R A M, Faivre, J, Martinez-Garcia, C, Pawlega, J, de Leon, M Ponz, Pottier, D, Raverdy, N, Williams, E M I, Berrino, F

“…BACKGROUND Marked differences in population based survival across Europe were found for colorectal cancers diagnosed in 1985–1989. AIMS To understand the…”
Get full text

Population-based survival rates after curative surgical and non-surgical treatment of stage III NSCLC since 2017 by Damhuis, R.A.M., Dickhoff, C., Bahce, I., Senan, S.

“…•The use of neoadjuvant treatment and surgery for stage III NSCLC decreased following the formal reimbursement of durvalumab.•Contemporary survival after…”
Get full text

Prognostic impact of KRAS mutation status for patients with stage IV adenocarcinoma of the lung treated with first-line pembrolizumab monotherapy by Noordhof, A.L., Damhuis, R.A.M., Hendriks, L.E.L., de Langen, A.J., Timens, W., Venmans, B.J.W., van Geffen, W.H.

“…•The overall survival of KRAS mutated versus KRAS wild-type NSCLC patients with PD-L1 ≥ 50 % is similar, when treated with first-line pembrolizumab.•KRAS has…”
Get full text

Trends in incidence, treatment and survival of patients with stage IV colorectal cancer: a population-based series by van der Pool, A. E. M., Damhuis, R. A., IJzermans, J. N. M., de Wilt, J. H. W., Eggermont, A. M. M., Kranse, R., Verhoef, C.

“…Aim  The incidence, patterns of care and survival were determined in patients with stage IV colorectal cancer (CRC) in a population‐based series. Method …”
Get full text

Association of molecular status and metastatic organs at diagnosis in patients with stage IV non-squamous non-small cell lung cancer by Kuijpers, C.C.H.J., Hendriks, L.E.L., Derks, J.L., Dingemans, A-M.C., van Lindert, A.S.R., van den Heuvel, M.M., Damhuis, R.A., Willems, S.M.

“…•NSCLC molecular status was associated with metastatic pattern at diagnosis.•EGFR+ tumors more often bone and pleural metastases than triple-negative.•EGFR+…”
Get full text

DLL3 expression in large cell neuroendocrine carcinoma (LCNEC) and association with molecular subtypes and neuroendocrine profile by Hermans, B.C.M., Derks, J.L., Thunnissen, E., van Suylen, R.J., den Bakker, M.A., Groen, H.J.M., Smit, E.F., Damhuis, R.A., van den Broek, E.C., Ruland, A., Speel, E.J.M., Dingemans, A.M.C.

“…•DLL3 is expressed in 74% of stage IV LCNEC patients•The majority (80%) has cytoplasmic/membranous expression•DLL3 is expressed in both SCLC- and NSCLC-like…”
Get full text

Treatment patterns and survival analysis in 9014 patients with malignant pleural mesothelioma from Belgium, the Netherlands and England by Damhuis, R.A, Khakwani, A, De Schutter, H, Rich, A.L, Burgers, J.A, van Meerbeeck, J.P

“…Highlights • Currently, more than half of mesothelioma patients are 70 years or older. • Chemotherapy use for mesothelioma varies between countries. • Survival…”
Get full text

Prevalence and prognostic value of PD-L1 expression in molecular subtypes of metastatic large cell neuroendocrine carcinoma (LCNEC) by Hermans, B.C.M., Derks, J.L., Thunnissen, E., van Suylen, R.J., den Bakker, M.A., Groen, H.J.M., Smit, E.F., Damhuis, R.A., van den Broek, E.C., Stallinga, C.M., Roemen, G.M., Speel, E.J.M., Dingemans, A.-M.C.

“…•PD-L1 ≥ 1% is expressed in 16% of stage IV LCNEC, 5% has expression ≥50%.•PD-L1 staining in LCNEC is comparable to values in SCLC, but lower than in NSCLC.•No…”
Get full text

Single organ metastatic disease and local disease status, prognostic factors for overall survival in stage IV non-small cell lung cancer: Results from a population-based study by Hendriks, L.E, Derks, J.L, Postmus, P.E, Damhuis, R.A, Houben, R.M.A, Troost, E.G.C, Hochstenbag, M.M, Smit, E.F, Dingemans, A.-M.C

“…Highlights • OS significantly longer in single organ metastatic disease compared to 2 or ⩾3 organs. • Single organ metastases also prognostic in subgroup of18…”
Get full text

Treatment Variation of Sequential versus Concurrent Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer Patients in the Netherlands and Belgium by Walraven, I., Damhuis, R.A., ten Berge, M.G., Rosskamp, M., van Eycken, L., de Ruysscher, D., Belderbos, J.S.A.

“…Concurrent chemoradiotherapy (CCRT) is considered the standard treatment regimen in non-surgical locally advanced non-small cell lung cancer (NSCLC) patients…”
Get full text

Resection rates and postoperative mortality in 7,899 patients with lung cancer by Damhuis, RA, Schutte, PR

“…Postoperative death used to be an important complication of resections for lung cancer, especially in elderly patients. To support decision making in a general…”
Get full text

A nationwide population-based cohort study of surgical care for patients with superior sulcus tumors: Results from the Dutch Lung Cancer Audit for Surgery (DLCA-S) by Winkelman, J.A., van der Woude, L., Heineman, D.J., Bahce, I., Damhuis, R.A., Mahtab, E.A.F., Hartemink, K.J., Senan, S., Maat, A.P.W.M., Braun, J., Paul, M.A., Dahele, M., Dickhoff, C.

“…•The resection rate of sulcus superior tumors in the Netherlands is 14.4%•1% of all pulmonary resections for lung cancer is for sulcus superior…”
Get full text

Patterns of care and outcomes for stage IIIB non-small cell lung cancer in the TNM-7 era: results from the Netherlands Cancer Registry by Dickhoff, C, Dahele, M, Smit, E.F, Paul, M.A, Senan, S, Hartemink, K.J, Damhuis, R.A

“…Highlights • National patterns of care and outcomes for stage IIIB in the TNM-7 era were analyzed. • The use of chemoradiotherapy for stage IIIB rapidly…”
Get full text

Determinants of improved survival after oesophagectomy for cancer by Talsma, A. K., Damhuis, R. A. M., Steyerberg, E. W., Rosman, C., van Lanschot, J. J. B., Wijnhoven, B. P. L.

“…Background Survival after oesophagectomy for cancer seems to be improving. This study aimed to identify the most important contributors to this change. Methods…”
Get full text

Prevalence and prognostic value of PD-L1 expression in molecular subtypes of metastatic large cell neuroendocrine carcinoma (LCNEC) by Hermans, B.C.M., Derks, J.L., Thunissen, E., van Suylen, R.J., den Bakker, M.A., Groen, H.J.M., Smit, E.F., Damhuis, R.A., van den Broek, E.C., PALGA-group, P., Stallinga, C.M., Roemen, G.M., Speel, E.J., Dingemans, A.-M.C.

Get full text

Lead Times and Overdetection Due to Prostate-Specific Antigen Screening: Estimates From the European Randomized Study of Screening for Prostate Cancer by Draisma, Gerrit, Boer, Rob, Otto, Suzie J., van der Cruijsen, Ingrid W., Damhuis, Ronald A. M., Schröder, Fritz H., de Koning, Harry J.

“…Background: Screening for prostate cancer advances the time of diagnosis (lead time) and detects cancers that would not have been diagnosed in the absence of…”
Get full text

Re-resection rates after breast-conserving surgery as a performance indicator: introduction of a case-mix model to allow comparison between Dutch hospitals by Talsma, A K, Reedijk, A M J, Damhuis, R A M, Westenend, P J, Vles, W J

“…Re-resection rate after breast-conserving surgery (BCS) has been introduced as an indicator of quality of surgical treatment in international literature. The…”
Get full text